1. Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related Autophagy Anti-infection Apoptosis
  2. Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis
  3. Daunorubicin

Daunorubicin  (Synonyms: Daunomycin; RP 13057; Rubidomycin)

Cat. No.: HY-13062A
Handling Instructions

Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Daunorubicin hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Daunorubicin Chemical Structure

Daunorubicin Chemical Structure

CAS No. : 20830-81-3

Size Stock
5 mg Get quote
10 mg Get quote
25 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Daunorubicin:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].

IC50 & Target[1][2]

Topoisomerase II

 

Daunorubicins/Doxorubicins

 

Cellular Effect
Cell Line Type Value Description References
4T1 IC50
0.3 μM
Compound: Daunorubicin
Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay
Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay
[PMID: 30654237]
4T1 IC50
40.8 nM
Compound: Dau
Cytostatic activity against mouse 4T1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against mouse 4T1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
A2058 IC50
33.3 nM
Compound: Dau
Cytostatic activity against human A2058 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human A2058 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
A2780 ADR GI50
0.01 μM
Compound: Daunorubicin
Inhibition of daunorubicin sensitive human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay
Inhibition of daunorubicin sensitive human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay
[PMID: 29016119]
A2780 ADR GI50
0.575 μM
Compound: Daunorubicin
Inhibition of cell growth in Daunorubicin resistant human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay
Inhibition of cell growth in Daunorubicin resistant human A2780 ADR cells expressing P-gp measured for 72 hrs by MTT assay
[PMID: 29016119]
A549 GI50
0.08 μM
Compound: daunorubicin
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
[PMID: 19968258]
A549 IC50
0.08 μM
Compound: Daunorubicin
Antiproliferative activity against human A549 cells by XTT assay
Antiproliferative activity against human A549 cells by XTT assay
[PMID: 25467291]
A549 IC50
0.15 μM
Compound: Daunorubicin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 30902399]
A549 IC50
0.51 μM
Compound: Daunorubicin
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 28923382]
A549 IC50
0.53 μM
Compound: Daunorubicin
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31431363]
A549 IC50
68.2 nM
Compound: Dau
Cytostatic activity against human A549 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human A549 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
ACHN IC50
63 nM
Compound: daunorubicin
Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay
[PMID: 17286393]
B16 EC50
0.16 μM
Compound: daunomycin
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.
Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.
[PMID: 11020285]
B16 IC50
8.9 nM
Compound: Dau
Cytostatic activity against mouse B16 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against mouse B16 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
BHK-21 IC50
0.09 μM
Compound: Daunorubicin
Cytotoxicity against BHK21 cells after 72 hrs by MTT assay
Cytotoxicity against BHK21 cells after 72 hrs by MTT assay
[PMID: 30654237]
COLO 205 IC50
0.5 μg/mL
Compound: daunorubicin
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
[PMID: 19606850]
CT26.WT IC50
0.42 μM
Compound: Daunorubicin
Cytotoxicity against mouse CT26.WT cells after 72 hrs by MTT assay
Cytotoxicity against mouse CT26.WT cells after 72 hrs by MTT assay
[PMID: 30654237]
CT26.WT IC50
126 nM
Compound: Dau
Cytostatic activity against mouse CT26.WT cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against mouse CT26.WT cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
DA-3 cell line IC50
1.9 μM
Compound: DNR
Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
[PMID: 24900668]
Detroit 551 GI50
1.77 μM
Compound: DAR
Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay
Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay
[PMID: 20591678]
DU-145 IC50
0.09 μM
Compound: DAU
Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay
Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay
[PMID: 22260166]
DU-145 IC50
24.5 nM
Compound: Dau
Cytostatic activity against human DU145 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human DU145 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
H69AR IC50
> 1000 nM
Compound: daunorubicin
Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay
Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay
[PMID: 17286393]
H69AR GI50
0.361 μM
Compound: Daunorubicin
Inhibition of daunorubicin sensitive human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay
Inhibition of daunorubicin sensitive human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay
[PMID: 29016119]
H69AR GI50
3.84 μM
Compound: Daunorubicin
Inhibition of cell growth in Daunorubicin resistant human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay
Inhibition of cell growth in Daunorubicin resistant human NCI-H69AR cells expressing MRP1 measured for 72 hrs by MTT assay
[PMID: 29016119]
HCT-116 IC50
0.21 μM
Compound: Daunorubicin
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31431363]
HCT-116 IC50
127.1 nM
Compound: Dau
Cytostatic activity against human HCT116 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human HCT116 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
HCT-15 IC50
> 400 nM
Compound: daunorubicin
Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay
[PMID: 17286393]
HEK293 IC50
1.2 μM
Compound: Daunonthicin
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by alamar blue assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by alamar blue assay
[PMID: 36449385]
HEK293 IC50
11.17 μM
Compound: Daunorubicin
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 28923382]
HEK293 IC50
11.17 μM
Compound: Daunorubicin
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31431363]
HEK293 IC50
12.55 μM
Compound: Daunorubicin
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar blue assay
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar blue assay
[PMID: 29190092]
HEK293 IC50
12.55 μM
Compound: Daunorubicin
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay
[PMID: 26937828]
HeLa IC50
2.96 μM
Compound: daunomycin
Cytotoxicity against human HeLa3 cell line by MTT assay
Cytotoxicity against human HeLa3 cell line by MTT assay
[PMID: 16942037]
HepG2 IC50
0.7 μM
Compound: Dauno
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
[PMID: 21094049]
HepG2 IC50
21.3 nM
Compound: Dau
Cytostatic activity against human HepG2 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human HepG2 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
HL-60 GI50
0.1 μM
Compound: Daunorubicin
Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis
Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis
[PMID: 25874335]
HL-60 IC50
15 nM
Compound: DAU
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
[PMID: 33750129]
HT-29 GI50
0.07 μM
Compound: daunorubicin
Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay
[PMID: 19968258]
HT-29 IC50
0.2 μM
Compound: Dau, daunomycin
Cytostatic activity against human HT-29 cells after 4 days by MTT assay
Cytostatic activity against human HT-29 cells after 4 days by MTT assay
[PMID: 22480495]
HT-29 IC50
0.4 μM
Compound: Dauno
Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay
Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay
[PMID: 21094049]
HT-29 IC50
133 nM
Compound: Daunomycin
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
[PMID: 2778449]
HT-29 IC50
202.9 nM
Compound: Dau
Cytostatic activity against human HT-29 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human HT-29 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
Jurkat IC50
82.6 nM
Compound: Daunorubicin
Cytotoxicity against Jurkat T lymphocytes by MTT assay
Cytotoxicity against Jurkat T lymphocytes by MTT assay
[PMID: 16366602]
K562 IC50
> 5 μM
Compound: DNR
Cytotoxicity against Dox-resistant K562 cells by MTS
Cytotoxicity against Dox-resistant K562 cells by MTS
[PMID: 16451059]
K562 GI50
0.0074 μM
Compound: DAR
Cytotoxicity against human K562 cells after 72 hrs by XTT assay
Cytotoxicity against human K562 cells after 72 hrs by XTT assay
[PMID: 20591678]
K562 IC50
0.45 μg/mL
Compound: daunorubicin
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
[PMID: 19606850]
K562 IC50
1.49 μg/mL
Compound: Daunorubicin
Cytotoxicity against human K562 cells after 6 hrs by MTT assay
Cytotoxicity against human K562 cells after 6 hrs by MTT assay
[PMID: 21493075]
K562 IC50
15 nM
Compound: DNR
Cytotoxicity against K562 cells by MTS
Cytotoxicity against K562 cells by MTS
[PMID: 16451059]
K562 IC50
15.2 μg/mL
Compound: daunorubicin
Cytotoxicity against human doxorubicin-resistant K562 cells after 48 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant K562 cells after 48 hrs by MTT assay
[PMID: 19606850]
K562 IC50
8.5 μg/mL
Compound: Daunorubicin
Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay
[PMID: 21493075]
KB IC50
0.22 μg/mL
Compound: daunorubicin
Cytotoxicity against human KB cells after 48 hrs by MTT assay
Cytotoxicity against human KB cells after 48 hrs by MTT assay
[PMID: 19606850]
KB IC50
0.45 μg/mL
Compound: Daunorubicin
Cytotoxicity against human KB cells after 6 hrs by MTT assay
Cytotoxicity against human KB cells after 6 hrs by MTT assay
[PMID: 21493075]
KB IC50
0.64 μM
Compound: Daunorubicin
Cytotoxicity against human KB cells after 48 hrs by MTT assay
Cytotoxicity against human KB cells after 48 hrs by MTT assay
[PMID: 20363142]
KB IC50
2.07 μM
Compound: DNR
In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells
In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells
10.1016/0960-894X(96)00457-X
KB IC50
2.07 μM
Compound: Daunomycin (DNR)
In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1
In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1
[PMID: 12443763]
KB 3-1 IC50
0.007 μM
Compound: DNR
In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells
In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells
10.1016/0960-894X(96)00457-X
KB 3-1 IC50
0.007 μM
Compound: Daunomycin (DNR)
In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1
In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1
[PMID: 12443763]
L1210 IC50
0.033 μM
Compound: DNR
In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.
In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.
10.1016/0960-894X(96)00457-X
L1210 IC50
0.04 μM
Compound: Daunomycin (DNR)
In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line
In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line
[PMID: 12443763]
L1210 ED50
0.3 μM
Compound: Daunomycin
Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis
Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis
[PMID: 176359]
L1210 ED50
0.3 μM
Compound: Daunomycin
Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis
Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis
[PMID: 176359]
L1210 ED50
0.33 μM
Compound: 2
Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.
Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.
[PMID: 7086816]
L1210 ED50
0.66 μM
Compound: 2
Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells
Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells
[PMID: 7086816]
L5178Y IC50
0.3 μM
Compound: liposomal daunorubicin, DaunoXome
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay
[PMID: 23199479]
L5178Y IC50
0.73 μM
Compound: Daunorubicin
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay
Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay
[PMID: 23199479]
L5178Y IC50
2.32 μM
Compound: liposomal daunorubicin, DaunoXome
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay
[PMID: 23199479]
L5178Y IC50
7.73 μM
Compound: Daunorubicin
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay
Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay
[PMID: 23199479]
LNCaP IC50
0.1 μM
Compound: Dau, daunomycin
Cytostatic activity against human LNCAP cells after 4 days by MTT assay
Cytostatic activity against human LNCAP cells after 4 days by MTT assay
[PMID: 22480495]
MCF7 IC50
0.033 μg/mL
Compound: Daunorubicin
Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay
[PMID: 21493075]
MCF7 IC50
0.33 μg/mL
Compound: daunorubicin
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 19606850]
MCF7 IC50
0.4 μM
Compound: Dau, daunomycin
Cytostatic activity against human MCF7 cells after 4 days by MTT assay
Cytostatic activity against human MCF7 cells after 4 days by MTT assay
[PMID: 22480495]
MCF7 IC50
0.5 μg/mL
Compound: Daunorubicin
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 21109433]
MCF7 IC50
0.56 μM
Compound: Daunorubicin
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31431363]
MCF7 IC50
0.65 μM
Compound: Daunorubicin
Antiproliferative activity against human MCF7 cells by XTT assay
Antiproliferative activity against human MCF7 cells by XTT assay
[PMID: 25467291]
MCF7 GI50
0.86 μM
Compound: DAR
Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
[PMID: 20591678]
MCF7 IC50
0.95 μM
Compound: DAU
Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay
[PMID: 22260166]
MCF7 IC50
1.44 μM
Compound: Daunorubicin
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 28923382]
MCF7 IC50
286 nM
Compound: Dau
Cytostatic activity against human MCF7 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human MCF7 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
MCF7 IC50
33.9 μM
Compound: DNR
Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
[PMID: 24900668]
MCF7 IC50
5.5 μM
Compound: Dauno
Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
[PMID: 21094049]
MDA-MB-231 GI50
0.02 μM
Compound: daunorubicin
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
[PMID: 19968258]
MDA-MB-231 IC50
0.091 μM
Compound: Daunorubicin
Antiproliferative activity against human MDA-MB-231 cells by XTT assay
Antiproliferative activity against human MDA-MB-231 cells by XTT assay
[PMID: 25467291]
MDA-MB-231 IC50
52.9 nM
Compound: Dau
Cytostatic activity against human MDA-MB-231 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human MDA-MB-231 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
MDA-MB-435 IC50
129 nM
Compound: Daunorubicin
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
[PMID: 17154505]
MDA-MB-435 IC50
79 nM
Compound: Daunorubicin
Antiproliferative activity against MDA435/LCC6 cells by ELISA
Antiproliferative activity against MDA435/LCC6 cells by ELISA
[PMID: 17154505]
MDA-MB-435 IC50
977 nM
Compound: Daunorubicin
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
[PMID: 17154505]
MES-SA IC50
0.021 μM
Compound: DNR
The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.
The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.
[PMID: 10698449]
MES-SA IC50
0.07 μM
Compound: Daunomycin (DNR)
In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA
In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA
[PMID: 12443763]
MES-SA IC50
20 nM
Compound: daunorubicin
Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay
Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay
[PMID: 17286393]
MES-SA IC50
3 μM
Compound: Daunomycin (DNR)
In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5
In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5
[PMID: 12443763]
MES-SA/Dx5 IC50
> 400 nM
Compound: daunorubicin
Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay
[PMID: 17286393]
MES-SA/Dx5 IC50
0.014 μM
Compound: DNR
The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.
The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.
[PMID: 10698449]
MES-SA/Dx5 IC50
2 μM
Compound: DNR
The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.
The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.
[PMID: 10698449]
MRC5 IC50
0.078 μM
Compound: Daunorubicin
Antiproliferative activity against human MRC5 cells by XTT assay
Antiproliferative activity against human MRC5 cells by XTT assay
[PMID: 25467291]
MRC5 IC50
254.7 nM
Compound: Dau
Cytostatic activity against human MRC5 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human MRC5 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
NCI/ADR-RES IC50
51.62 μM
Compound: Daunorubicin
Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
[PMID: 33725657]
NCI/ADR-RES IC50
7.12 μM
Compound: Daunomycin
Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay
Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay
[PMID: 28246041]
NCI-H1299 IC50
0.096 μM
Compound: Daunorubicin
Antiproliferative activity against human H1299 cells by XTT assay
Antiproliferative activity against human H1299 cells by XTT assay
[PMID: 25467291]
NCI-H1650 IC50
47.5 nM
Compound: Dau
Cytostatic activity against human NCI-H1650 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human NCI-H1650 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
NCI-H1975 IC50
13.3 nM
Compound: Dau
Cytostatic activity against human NCI-H1975 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human NCI-H1975 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
NCI-H460 GI50
0.38 μM
Compound: DAR
Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
[PMID: 20591678]
NCI-H69 IC50
100 nM
Compound: daunorubicin
Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay
Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay
[PMID: 17286393]
NIH3T3 IC50
0.044 μM
Compound: Dounorubicin
Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay
Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay
[PMID: 18954040]
NIH3T3 IC50
1.01 μM
Compound: Dounorubicin
Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay
Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay
[PMID: 18954040]
NIH3T3 IC50
1.8 μM
Compound: Dauno
Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay
Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay
[PMID: 21094049]
OVCAR-3 IC50
472.9 nM
Compound: Dau
Cytostatic activity against human OVCAR3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human OVCAR3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
P388 IC50
25 nM
Compound: Daunorubicin
Antiproliferative activity against P388 cells by ELISA
Antiproliferative activity against P388 cells by ELISA
[PMID: 17154505]
P388 IC50
28 nM
Compound: Daunomycin
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
[PMID: 2778449]
P388/ADR IC50
106 nM
Compound: Daunorubicin
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
[PMID: 17154505]
P388/ADR IC50
2111 nM
Compound: Daunorubicin
Antiproliferative activity against adriamycin resistant P388 cells by ELISA
Antiproliferative activity against adriamycin resistant P388 cells by ELISA
[PMID: 17154505]
P388/ADR IC50
40 nM
Compound: Daunorubicin
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA
[PMID: 17154505]
PANC-1 IC50
466.7 nM
Compound: Dau
Cytostatic activity against human PANC1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human PANC1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
PC-3 IC50
26 nM
Compound: Dau
Cytostatic activity against human PC3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human PC3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
RD IC50
2.45 μM
Compound: Daunorubicin
Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 28923382]
RD IC50
2.45 μM
Compound: Daunorubicin
Antiproliferative activity against human RD cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human RD cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31431363]
SF-268 GI50
0.6 μM
Compound: DAR
Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
[PMID: 20591678]
SK-MES-1 IC50
0.17 μM
Compound: DAU
Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay
Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay
[PMID: 22260166]
SK-OV-3 IC50
20.6 μM
Compound: DNR
Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
[PMID: 24900668]
THP-1 IC50
26.9 μM
Compound: DNM
Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay
Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay
[PMID: 22939695]
U-87MG ATCC IC50
27.9 nM
Compound: Dau
Cytostatic activity against human U87 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human U87 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
Vero IC50
2.5 μM
Compound: Dauno
Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay
Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay
[PMID: 21094049]
WiDr IC50
240.1 nM
Compound: Dau
Cytostatic activity against human WiDr cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
Cytostatic activity against human WiDr cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay
[PMID: 31100648]
In Vitro

Daunorubicin (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2].
Daunorubicin (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4].
Daunorubicin (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4].
Daunorubicin (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4].
Daunorubicin (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3][4]

Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
Concentration: 7 nM-1.9 μM
Incubation Time: 72 h
Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6).

Apoptosis Analysis[4]

Cell Line: L3.6 cells
Concentration: 0.4 μM
Incubation Time: 24 h, 48 h
Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.

Western Blot Analysis[6]

Cell Line: K562 cells
Concentration: 2 μM
Incubation Time: 24 h
Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.
In Vivo

Daunorubicin (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats[5].
Daunorubicin (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats[5]
Dosage: 3 mg/kg
Administration: Intravenous injection, three times at 48 h intervals.
Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
Increased urinary protein excretion, serum creatinine, and BUN level.
Clinical Trial
Molecular Weight

527.52

Formula

C27H29NO10

CAS No.
SMILES

O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O

Structure Classification
Initial Source

Streptomyces peucetius and S. peucetius subsp. caesius

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Daunorubicin
Cat. No.:
HY-13062A
Quantity:
MCE Japan Authorized Agent: